| AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis | Oxford vaccine effective against major B |
|---|---|
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine AZD1222 against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK | Woo, Jenny Strasburg and Stu October 21, 2020 |
| Where is the Oxford-AstraZeneca vaccine made? Department of Health and Social Care | They then added the Spike gene to the adenovirus vector |
|---|---|
| ChAdOx1nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B |
This trains our immune system so when we encounter , we can mount a defense.
22| Wise, Jacqui 5 February 2021 | "A Phase III study to investigate a vaccine against COVID-19" |
|---|---|
| So they took an adenovirus that normally infects chimpanzees, and genetically altered it so it can no longer replicate or cause disease | It just trains our immune system to quickly recognize that part of the virus |